Credit Industriel ET Commercial Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)

Credit Industriel ET Commercial bought a new position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 609,855 shares of the biotechnology company's stock, valued at approximately $4,537,000. Grifols makes up about 0.6% of Credit Industriel ET Commercial's portfolio, making the stock its 22nd biggest position. Credit Industriel ET Commercial owned 0.09% of Grifols at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GRFS. Cigogne Management SA acquired a new position in shares of Grifols in the fourth quarter valued at approximately $1,778,000. Syon Capital LLC acquired a new position in Grifols in the fourth quarter valued at approximately $197,000. Stifel Financial Corp boosted its stake in Grifols by 5.5% during the fourth quarter. Stifel Financial Corp now owns 123,878 shares of the biotechnology company's stock worth $922,000 after acquiring an additional 6,417 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 6,335 shares in the last quarter. Finally, Capital World Investors grew its stake in Grifols by 0.7% in the fourth quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company's stock valued at $157,239,000 after acquiring an additional 154,358 shares during the period.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GRFS. Morgan Stanley started coverage on shares of Grifols in a report on Wednesday, February 12th. They set an "overweight" rating for the company. Wall Street Zen raised Grifols from a "hold" rating to a "buy" rating in a report on Friday.

Grifols Stock Performance

Shares of NASDAQ:GRFS traded up $0.12 during midday trading on Tuesday, reaching $8.23. The company had a trading volume of 714,892 shares, compared to its average volume of 1,159,439. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The company's 50 day moving average price is $7.31 and its 200 day moving average price is $7.57. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The stock has a market cap of $5.66 billion, a P/E ratio of 7.03 and a beta of 0.44.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.